Franklin Resources’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-11,380
| Closed | -$458K | – | 3201 |
|
|
2026
Q1 | $458K | Buy |
11,380
+76
| +0.7% | +$1.64K | ﹤0.01% | 2501 |
|
|
2025
Q4 | $284K | Buy |
+11,304
| New | +$265K | ﹤0.01% | 2647 |
|
|
2024
Q4 | – | Sell |
-215,289
| Closed | -$5.89M | – | 2924 |
|
|
2024
Q3 | $5.89M | Sell |
215,289
-10,643
| -5% | -$394K | ﹤0.01% | 1294 |
|
|
2024
Q2 | $8.67M | Sell |
225,932
-717
| -0.3% | -$32.5K | ﹤0.01% | 1127 |
|
|
2024
Q1 | $13.3M | Sell |
226,649
-3,141
| -1% | -$200K | ﹤0.01% | 985 |
|
|
2023
Q4 | $13.8M | Buy |
+229,790
| New | +$11.7M | 0.01% | 856 |
|
|
2023
Q3 | – | Sell |
-165,710
| Closed | -$15.1M | – | 2665 |
|
|
2023
Q2 | $15.1M | Buy |
165,710
+65,449
| +65% | +$5.65M | 0.01% | 836 |
|
|
2023
Q1 | $6.61M | Buy |
+100,261
| New | +$5.79M | ﹤0.01% | 1027 |
|
|
2022
Q4 | – | Sell |
-3,337
| Closed | -$228K | – | 2330 |
|
|
2022
Q3 | $228K | Buy |
+3,337
| New | +$197K | ﹤0.01% | 1952 |
|
|
2021
Q4 | – | Sell |
-610,339
| Closed | -$20.1M | – | 2473 |
|
|
2021
Q3 | $20.1M | Buy |
+610,339
| New | +$34.3M | 0.01% | 896 |
|
Other funds holding APLS
Franklin Resources's APLS Position: Q2 2026 in Review
Franklin Resources sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 11,380 shares — an estimated $458K sold.
Franklin Resources first reported a position in APLS in Q3 2021 and held it in 10 quarters. The position peaked at $20.1M in Q3 2021. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Franklin Resources reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Franklin Resources sold 11,380 Apellis Pharmaceuticals shares in Q2 2026, an estimated $458K.
- Franklin Resources first reported a position in Apellis Pharmaceuticals in Q3 2021 and held it in 10 quarters.
- Franklin Resources's Apellis Pharmaceuticals position peaked at $20.1M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Franklin Resources's 13F filing for Q2 2026, filed 13 Aug 2026.